Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone.

Humans Angiogenesis Inhibitors / adverse effects Ranibizumab / adverse effects Immune Checkpoint Inhibitors / adverse effects Vascular Endothelial Growth Factor A Neoplasms / drug therapy Cardiotoxicity / etiology Randomized Controlled Trials as Topic
Angiogenesis inhibitors Cardiovascular toxicity Immune checkpoint inhibitors

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 29 04 2023
revised: 04 06 2023
accepted: 19 06 2023
medline: 27 7 2023
pubmed: 24 6 2023
entrez: 23 6 2023
Statut: ppublish

Résumé

Anti-VEGF (vascular endothelial growth factor) agents were associated with increased risk of several cardiovascular events, while one meta-analysis did not show any significantly increased risk of cardiotoxicity associated with the use of immune checkpoint inhibitors (ICIs). This meta-analysis of randomized-controlled trials (RCTs) was designed to compare cardiovascular toxicity of anti-VEGF agents plus ICI vs anti-VEGF agents without ICIs. A systematic search of the literature was conducted to include all full papers reporting about phase II and III randomized controlled trials (RCTs) conducted in patients with solid malignancies randomized to an anti-VEGF agent plus an ICI vs. an anti-VEGF agent without an ICI. Overall incidences of cardiovascular events were compared between these two treatment groups estimating the corresponding odds ratios. This analysis suggests that ICIs may increase the risk of cardiovascular toxicities associated with anti-VEGF therapies. Further research, including real world studies, is warranted.

Identifiants

DOI: 10.1016/j.critrevonc.2023.104059 PMID: 37353178
pubmed: 37353178
pii: S1040-8428(23)00147-6
doi: 10.1016/j.critrevonc.2023.104059
pii:
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Ranibizumab ZL1R02VT79
Immune Checkpoint Inhibitors 0
Vascular Endothelial Growth Factor A 0

Types de publication

Meta-Analysis Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104059

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest

Auteurs

Felice Crocetto (F)

Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. Electronic address: felice.crocetto@unina.it.

Matteo Ferro (M)

Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy.

Carlo Buonerba (C)

Associazione O.R.A.-Oncology Research Assistance, 80049 Somma Vesuviana, Italy; Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy.

Luca Bardi (L)

Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy.

Pasquale Dolce (P)

Department of Public Health, Federico II University of Naples, Naples, Italy.

Luca Scafuri (L)

Associazione O.R.A.-Oncology Research Assistance, 80049 Somma Vesuviana, Italy; Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy.

Benito Fabio Mirto (BF)

Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.

Antonio Verde (A)

Associazione O.R.A.-Oncology Research Assistance, 80049 Somma Vesuviana, Italy; Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy.

Antonella Sciarra (A)

Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, NA, Italy.

Biagio Barone (B)

Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.

Armando Calogero (A)

Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples 80131, Italy.

Caterina Sagnelli (C)

Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania "Luigi Vanvitelli", Naples 80138, Italy.

Gian Maria Busetto (GM)

Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy.

Francesco Del Giudice (F)

Department of Maternal Infant and Urological Sciences, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy.

Simone Cilio (S)

Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.

Guru Sonpavde (G)

Division of Medical Oncology, Advent Health Cancer Institute, Orlando, FL, USA.

Rossella Di Trolio (R)

Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.

Giuseppe Luca Della Ratta (GL)

Cardiology Unity, Humanitas Gavazzeni, Bergamo, Italy.

Gabriele Barbato (G)

Department of Anesthesia and Intensive Care, "Anastasia Guerriero" Hospital, Caserta Local Health Authority, Marcianise, Caserta, Italy.

Giuseppe Di Lorenzo (G)

Associazione O.R.A.-Oncology Research Assistance, 80049 Somma Vesuviana, Italy; Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy; Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, 86100 Campobasso, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Comparing cardiovascular adverse events in...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Inhibiteurs de l'angiogenèse › Comparing cardiovascular adverse events in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Ranibizumab › Comparing cardiovascular adverse events in...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Inhibiteurs de points de contrôle immunitaires › Comparing cardiovascular adverse events in...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Protéines angiogéniques › Facteurs de croissance endothéliale vasculaire › Facteur de croissance endothéliale vasculaire de type A › Comparing cardiovascular adverse events in...
questionsmedicales.fr › Tumeurs › Comparing cardiovascular adverse events in...
questionsmedicales.fr › Phénomènes physiques › Rayonnement › Cardiotoxicité › Comparing cardiovascular adverse events in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques contrôlés comme sujet › Essais contrôlés randomisés comme sujet › Comparing cardiovascular adverse events in...